Nuvalent, Inc.
NUVL
Classement en actions
#2115
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Prix de l'action
$123.96
Dernière synchronisation: 2026-07-21
Capitalisation boursière
$9.75B
Changement (1 jour)
0.00%
Changement (1 an)
27.56%
Pays
US
Échange Nuvalent, Inc. (NUVL)
Catégorie
Healthcare
Bénéfices pour Nuvalent, Inc. (NUVL)
Bénéfices en Mar 2026 TTM : $-449.48M
Selon les derniers rapports financiers de Nuvalent, Inc., les bénéfices actuels de l'entreprise sont de $-449.48M. En 2023, l'entreprise a réalisé un bénéfice de $-126.22M, une diminution par rapport à celui de 2022 qui était de $-81.85M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Nuvalent, Inc. de 2019 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-449.48M | 72.88% |
| 2024 | $-259.99M | 105.98% |
| 2023 | $-126.22M | 54.20% |
| 2022 | $-81.85M | 76.65% |
| 2021 | $-46.34M | 218.34% |
| 2020 | $-14.56M | 23.26% |
| 2019 | $-11.81M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -1,273.56% |
US
|
|
| $-3.09B | 586.80% |
US
|
|
| $-4.02B | 793.52% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -533.98% |
NL
|
